

20 April 2021

Bould Opportunities plc

("Bould Opportunities", "Bould" or the "Company")

Corporate Update

Notice of Annual General Meeting

Bould Opportunities is pleased to announce a corporate update, including further details regarding the Company's proposed acquisition of a company focussed on early cancer detection (the "Proposed Transaction"), the intention for the Company's shares to be admitted to the Standard Listing segment of the Official List and trading on the Main Market of the London Stock Exchange ("Admission") and a notice of the Company's Annual General Meeting.

The Company anticipates that it will be in a position to announce full details of the Proposed Transaction, publish the prospectus required for Admission and post a notice of the required General Meeting to approve the proposals within the next seven days. It is anticipated that the General Meeting will be held on the same day as the Annual General Meeting. Shareholders should note any General Meeting convened by the Company requires a shorter notice period to be given to shareholders than that required for the Company's Annual General Meeting.

Highlights

- The Company has conditionally agreed to acquire a company which is a university spin-out focused on patent protected technology for the early detection of lung cancer.
- A prospectus will be published in connection with the proposed Admission of the Company's shares to the Standard Listing segment of the Official List and trading on the Main Market of the London Stock Exchange.
- The proposals will be subject to Bould shareholder approval at a General Meeting.
- The Company anticipates announcing full details of the Proposed Transaction and publishing a prospectus on or before 27 April 2021.
- Should the proposals be approved by Bould shareholders at a to be convened General Meeting the Company anticipates that its shares will be admitted to trading on the London Stock Exchange on or shortly after 14 May 2021.

Commenting Allan Syms, Chairman of Bould Opportunities, said: "I am delighted that we are finally at the stage where we will shortly be able to provide full details of the proposed acquisition of a very exciting company that has developed a simple blood test for the early detection of lung cancer.

"According to Cancer Research UK, in 2018 there were 17 million new cases of lung cancer globally and the situation is getting even worse with a predicted 27 million cases by 2040. The

sad fact is that lung cancer is difficult to diagnose early enough to treat effectively, and consequently in 2018 over 9 million people lost their lives to this disease. A major factor in beating lung cancer is the stage at which it is diagnosed. Almost 9 in 10 lung cancer patients will survive their disease for at least a year if diagnosed at the earliest stage. This falls to around only 1 in 5 people when lung cancer is diagnosed at the most advanced stage. Fundamentally, early detection can save lives.

“It is essential that we diagnose early and start appropriate treatment regimens at the earliest opportunity. However, lung cancer is exceedingly difficult to diagnose at an early stage. At its earliest stage there are few clinical symptoms and as a result emergency presentation, caused by for example investigation of a rib injury or infection, is a common route to diagnosing lung cancer.

“However, I believe that the company we are proposing to acquire can provide a solution to this problem through the blood test it is developing for the early detection of a majority of the different forms of lung cancer.

“I believe that this acquisition presents a compelling potential value opportunity for the Company, with a technology looking to address an urgent clinical need. I would like to thank the Bould shareholders for their considerable and continuing patience and hope that they support the proposals when they are announced.”

Notice of Annual General Meeting

The Annual General Meeting of the Company will be held at the offices of Goodman Derrick LLP, 5th Floor, 10 St Bride Street, London EC4A 4AD on 13 May 2021 at 11.00 a.m.

The Notice of Annual General Meeting has been posted to shareholders, together with arrangements for the meeting in light of the ongoing Covid-19 related restrictions.

Investor webinar

There will be the opportunity for shareholders to hear more about the proposals and submit questions at an online investor webinar ahead of the Annual General Meeting, details of which will be announced alongside full details of the proposals.

For further information:

Bould Opportunities plc
Allan Syms, Chairman

c/o IFC Advisory

IFC Advisory Limited (Financial PR & IR)
Tim Metcalfe
Florence Chandler

+44(0)20 3934 6630
bould@investor-focus.co.uk